Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen

Exp Hematol. 2011 Dec;39(12):1117-8. doi: 10.1016/j.exphem.2011.09.003. Epub 2011 Sep 12.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Boronic Acids / administration & dosage
  • Boronic Acids / pharmacology*
  • Bortezomib
  • Combined Modality Therapy
  • Dexamethasone / administration & dosage
  • Drug Resistance, Neoplasm / genetics*
  • Epirubicin / administration & dosage
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / genetics
  • Multiple Myeloma / radiotherapy
  • Neoplasm Proteins / biosynthesis
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / physiology*
  • Proteasome Endopeptidase Complex / biosynthesis
  • Proteasome Endopeptidase Complex / genetics
  • Proteasome Endopeptidase Complex / physiology*
  • Pyrazines / administration & dosage
  • Pyrazines / pharmacology*
  • Thalidomide / administration & dosage
  • Up-Regulation

Substances

  • Angiogenesis Inhibitors
  • Boronic Acids
  • Neoplasm Proteins
  • Pyrazines
  • Epirubicin
  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • PSMB5 protein, human
  • Proteasome Endopeptidase Complex